Bryon Evans, MD
Psychiatry · Atlanta, GANPI 1942280011
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $167,402 of the $211,357 with a category attached, or 79.2%. 42 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 41.5% of the total. 2025 is the largest year on record at $123,446, more than ten times the $1,580 reported in 2019. Among psychiatry clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,175 payments — averaging $179.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$88K
- Otsuka America Pharmaceutical, Inc.$66K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$32K
- Alkermes, Inc.$8K
- Johnson & Johnson$6K
- Neurocrine Biosciences, Inc.$1K
- plus $11K from 36 others
What the payments were for
- Consulting fees$5,5003%
- Speaking & faculty fees$167,40279%
- Travel & lodging$14,8937%
- Food & beverage$23,54811%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$85,545
- REXULTI$63,289
- CAPLYTA$29,636
- ARISTADA$27,746
- ARISTADA INITIO$6,936
- SPRAVATO$4,999
- INGREZZA$362
- Orphengesic Forte$211
- Fanapt$125
How this compares
$211,357 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 67 | $226,514 |
| AustedoDeutetrabenazine | 18 | $114,602 |
| Invega TrinzaPaliperidone Palmitate | 12 | $100,889 |
| IngrezzaValbenazine Tosylate | 13 | $91,969 |
| SpravatoEsketamine Hcl | 51 | $76,436 |
| LybalviOlanzapine/Samidorphan Malate | 26 | $41,016 |
| Abilify MaintenaAripiprazole | 14 | $39,263 |
| VraylarCariprazine Hcl | 26 | $36,286 |
| CaplytaLumateperone Tosylate | 23 | $36,172 |
| TrintellixVortioxetine Hydrobromide | 40 | $23,666 |
| RexultiBrexpiprazole | 11 | $14,982 |
| Chlorpromazine Hcl | 87 | $12,909 |
| Aripiprazole | 146 | $11,685 |
| Lurasidone Hcl | 40 | $10,345 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 305 | $10,255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Spravato | $6,207 | $403,840130 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,102 | $114,60218 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,397 | $91,96913 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $65,603 | $54,24525 claims |
| Alkermes, Inc.Lybalvi | $8,138 | $41,01626 claims |
| AbbVieVraylar | $684 | $36,28626 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $31,627 | $36,17223 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $993 | $23,66640 claims |
| MerckBelsomra | $43 | $8,56920 claims |
| Lilly USA, LLCOlanzapine | $23 | $2,695127 claims |
| Almatica Pharma LLCSertraline Hcl | $162 | $2,160335 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Atlanta
- David PurselleAtlanta$307K
- Michael BurkeAtlanta$217K
- Kerry ResslerAtlanta$196K
- Patricio Riva PosseAtlanta$122K
- Ray HorwitzAtlanta$64K
- Boadie DunlopAtlanta$61K
- Zohaib HaqueAtlanta$49K
- Raymond KotwickiAtlanta$44K
- Joseph BergerAtlanta$24K
- Dwight OwensAtlanta$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.